Limb-Girdle Muscular Dystrophy (LGMD) Sequencing Panel

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits


Test Code Test Copy GenesCPT Code Copy CPT Codes
1345 ANO5 81406 Add to Order
CAPN3 81406
CAV3 81404
DES 81405
DNAJB6 81479
DYSF 81408
FKRP 81404
FKTN 81405
GAA 81406
GMPPB 81479
ISPD 81405
LIMS2 81479
LMNA 81406
MYOT 81405
PLEC 81479
PNPLA2 81479
POMGNT1 81406
POMK 81479
POMT1 81406
POMT2 81406
SGCA 81405
SGCB 81405
SGCD 81405
SGCG 81405
SMCHD1 81479
TCAP 81479
TNPO3 81479
TOR1AIP1 81479
TRAPPC11 81479
TRIM32 81479
TTN 81479
VCP 81479
Full Panel Price* $640
Test Code Test Copy Genes Total Price CPT Codes Copy CPT Codes
1345 Genes x (33) $640 81404(x2), 81405(x8), 81406(x7), 81408, 81479(x15) Add to Order

New York State Approved Test

Pricing Comments

We are happy to accommodate requests for single genes or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered on our PGxome Custom Panel.

Targeted Testing

For ordering sequencing of targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 20 days.

Clinical Sensitivity

Many of the Limb-Girdle Muscular Dystrophy (LGMD) subtypes are ultra-rare disorders and clinical sensitivity cannot be estimated. In a large cohort of North American LGMD patients Moore et al. (2006) made a diagnosis of dysferlinopathy in 18% of the cohort using a combined immunological and molecular approach, making LGMD2B the most common cause of LGMD in this mixed population. Childhood onset LGMD is more likely to be caused by defects in the sarcoglycan genes (Vainzof et al. 1999) and late onset LGMD often results from pathogenic variants in the ANO5 gene (Sarkozy et al. 2013).

See More

See Less

CNV via aCGH

Test Code Test Copy GenesPriceCPT Code Copy CPT Codes
600 ANO5$990 81479 Add to Order
CAPN3$990 81479
CAV3$990 81479
DES$990 81479
DNAJB6$990 81479
DYSF$990 81479
FKRP$990 81479
FKTN$990 81479
GAA$990 81479
GMPPB$990 81479
ISPD$990 81479
LIMS2$990 81479
LMNA$990 81479
MYOT$990 81479
PLEC$990 81479
PNPLA2$990 81479
POMGNT1$990 81479
POMK$990 81479
POMT1$990 81479
POMT2$990 81479
SGCA$990 81479
SGCB$990 81479
SGCD$990 81479
SGCG$990 81404
SMCHD1$990 81479
TCAP$990 81479
TNPO3$990 81479
TOR1AIP1$990 81479
TRAPPC11$990 81479
TRIM32$990 81479
TTN$990 81479
VCP$990 81479
Full Panel Price* $1490
Test Code Test Copy Genes Total Price CPT Codes Copy CPT Codes
600 Genes x (32) $1490 81404, 81479(x31) Add to Order
Pricing Comments

# of Genes Ordered

Total Price









Over 100

Call for quote

Turnaround Time

The great majority of tests are completed within 20 days.

Clinical Sensitivity

Many of the genes in this panel have no or very few large deletions/duplications reported, indicating clinical sensitivity would be low for this panel. However, the DYSF, GAA, and SGCG genes have a higher proportion of gross deletions/duplications reported and could be considered for aCGH testing (Human Gene Mutation Database).

See More

See Less

Clinical Features

Limb girdle muscular dystrophy (LGMD) is a descriptive term for a group of disorders with atrophy and weakness of proximal limb girdle muscles, typically sparing the heart and bulbar muscles. Clinical severity, age of onset, and disease progression are highly variable among the subtypes (Sáenz et al. 2005). Serum creatine kinase levels are typically elevated, and muscle biopsies demonstrate a dystrophic process. For a comprehensive review see Pegoraro and Hoffman (2012).


Over twenty genes have been implicated in recessively inherited limb girdle muscular dystrophy: ANO5, CAPN3, DYSF, FKRP, FKTN, GMPPB, ISPD, LIMS2, PNPLA2, SGCA, SGCB, SGCD, SGCG, TCAP, TOR1AIP1, TRAPPC11, TRIM32, PLEC, POMGNT1, POMK, POMT1, POMT2, and GAA. Pathogenic variants in these genes include missense, nonsense, splicing, small deletions/insertions, and a few large deletions/duplications (Human Gene Mutation Database). The most common forms include LGMD2A, LGMD2B, and LGMD2I, caused by pathogenic variants in the CAPN3, DYSF, and FKRP genes, respectively (Moore et al. 2006; Pegoraro and Hoffman 2012). The CAV3, DES, LMNA, and TTN genes can exhibit both recessive and dominant inheritance.

Dominant forms of limb girdle muscular dystrophy include LGMD1A, LGMD1B, LGMD1C, LGMD1E, LGMD1F, LGMD1G caused by pathogenic variants in the MYOT, LMNA, CAV3, DNAJB6, TNPO3, and HNRNPDL genes, respectively. Another dominantly inherited muscular dystrophy with a limb girdle pattern of weakness is facioscapulohumeral muscular dystrophy 2 (FSHD2). This is caused by the combination of a heterozygous mutation in the SMCHD1 gene on chromosome 18p and presence of a haplotype on chromosome 4 that is permissive for DUX4 expression. The VCP gene can also cause limb girdle-like weakness and is inherited in an autosomal dominant manner.

See individual gene test descriptions for information on molecular biology of gene products.

Testing Strategy

For this NextGen test, the full coding regions plus ~10 bp of non-coding DNA flanking each exon are sequenced for each of the genes listed below. Sequencing is accomplished by capturing specific regions with an optimized solution-based hybridization kit, followed by massively parallel sequencing of the captured DNA fragments. Additional Sanger sequencing is performed for any regions not captured or with insufficient number of sequence reads.

Of note, this testing includes coverage of FKTN deep intronic variant c.647+2084G>T.

This panel does not include analysis of TTN exons 85-95. Sanger coverage of these regions is available upon request; however, very few pathogenic variants have been reported in these exons (Human Gene Mutation Database).

This test will cover over 99% of the coding exons in the indicated genes plus flanking regions.

Indications for Test

Individuals with a limb girdle pattern of muscle weakness and atrophy.


Name Inheritance OMIM ID
Autosomal Dominant Limb-Girdle Muscular Dystrophy, Type 1E AD 603511
Facioscapulohumeral Muscular Dystrophy 2 AR 158901
Glycogen Storage Disease Type II AR 232300
Inclusion Body Myopathy With Early-Onset Paget Disease And Frontotemporal Dementia AD 167320
Limb-Girdle Muscular Dystrophy, Type 1A AR 159000
Limb-Girdle Muscular Dystrophy, Type 1B AD 159001
Limb-Girdle Muscular Dystrophy, Type 1F AD, AR 608423
Limb-Girdle Muscular Dystrophy, Type 2A AR 253600
Limb-Girdle Muscular Dystrophy, Type 2B AR 253601
Limb-Girdle Muscular Dystrophy, Type 2D AD 608099
Limb-Girdle Muscular Dystrophy, Type 2E AR 604286
Limb-Girdle Muscular Dystrophy, Type 2F AD, AR 601287
Limb-Girdle Muscular Dystrophy, Type 2G AD 601954
Limb-Girdle Muscular Dystrophy, Type 2H AD, AR 254110
Limb-Girdle Muscular Dystrophy, Type 2Y AR 617072
Muscular Dystrophy, Limb Girdle, Type 2C AR 253700
Muscular Dystrophy, Limb-Girdle, Type 1C AD, AR 607801
Muscular Dystrophy, Limb-Girdle, Type 1G AD 609115
Muscular Dystrophy, Limb-Girdle, Type 2J AR 608807
Muscular Dystrophy, Limb-Girdle, Type 2L AR 611307
Muscular Dystrophy, Limb-Girdle, Type 2Q AR 613723
Muscular dystrophy, limb-girdle, type 2R AR 615325
Muscular dystrophy, limb-girdle, type 2S AD, AR 615356
Muscular Dystrophy, Limb-Girdle, Type 2W AR 616827
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12 AR 615249
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7 AR 614643
Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 1 AR 609308
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14 AR 615352
Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 2 AR 613158
Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 3 AR 613157
Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 4 AR 611588
Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 5 AR 607155
Neutral Lipid Storage Disease With Myopathy AR 610717

Related Test



Genetic Counselors
  • Human Gene Mutation Database (Bio-base).
  • Moore S.A. et al. 2006. Journal of Neuropathology and Experimental Neurology. 65: 995-1003. PubMed ID: 17021404
  • Pegoraro E, Hoffman EP. 2012. Limb-Girdle Muscular Dystrophy Overview. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, and Stephens K, editors. GeneReviews™, Seattle (WA): University of Washington, Seattle. PubMed ID: 20301582
  • Sáenz A. et al. 2005. Brain. 128: 732-42. PubMed ID: 15689361
  • Sarkozy A. et al. 2013. Human Mutation. 34: 1111-8. PubMed ID: 23606453
  • Vainzof M. et al. 1999. Journal of the Neurological Sciences. 164: 44-9. PubMed ID: 10385046
Order Kits

NextGen Sequencing using PG-Select Capture Probes

Test Procedure

We use a combination of Next Generation Sequencing (NGS) and Sanger sequencing technologies to cover the full coding regions of the listed genes plus ~10 bases of non-coding DNA flanking each exon.  As required, genomic DNA is extracted from the patient specimen.  For NGS, patient DNA corresponding to these regions is captured using an optimized set of DNA hybridization probes.  Captured DNA is sequenced using Illumina’s Reversible Dye Terminator (RDT) platform (Illumina, San Diego, CA, USA).  Regions with insufficient coverage by NGS are often covered by Sanger sequencing.

For Sanger sequencing, Polymerase Chain Reaction (PCR) is used to amplify targeted regions.  After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.

Patient DNA sequence is aligned to the genomic reference sequence for the indicated gene region(s). All differences from the reference sequences (sequence variants) are assigned to one of five interpretation categories, listed below, per ACMG Guidelines (Richards et al. 2015).

(1) Pathogenic Variants
(2) Likely Pathogenic Variants
(3) Variants of Uncertain Significance
(4) Likely Benign Variants
(5) Benign Variants

Human Genome Variation Society (HGVS) recommendations are used to describe sequence variants (  Rare variants and undocumented variants are nearly always classified as likely benign if there is no indication that they alter protein sequence or disrupt splicing.

Analytical Validity

As of March 2016, 6.36 Mb of sequence (83 genes, 1557 exons) generated in our lab was compared between Sanger and NextGen methodologies. We detected no differences between the two methods. The comparison involved 6400 total sequence variants (differences from the reference sequences). Of these, 6144 were nucleotide substitutions and 256 were insertions or deletions. About 65% of the variants were heterozygous and 35% homozygous. The insertions and deletions ranged in length from 1 to over 100 nucleotides.

In silico validation of insertions and deletions in 20 replicates of 5 genes was also performed. The validation included insertions and deletions of lengths between 1 and 100 nucleotides. Insertions tested in silico: 2200 between 1 and 5 nucleotides, 625 between 6 and 10 nucleotides, 29 between 11 and 20 nucleotides, 25 between 21 and 49 nucleotides, and 23 at or greater than 50 nucleotides, with the largest at 98 nucleotides. All insertions were detected. Deletions tested in silico: 1813 between 1 and 5 nucleotides, 97 between 6 and 10 nucleotides, 32 between 11 and 20 nucleotides, 20 between 21 and 49 nucleotides, and 39 at or greater than 50 nucleotides, with the largest at 96 nucleotides. All deletions less than 50 nucleotides in length were detected, 13 greater than 50 nucleotides in length were missed. Our standard NextGen sequence variant calling algorithms are generally not capable of detecting insertions (duplications) or heterozygous deletions greater than 100 nucleotides. Large homozygous deletions appear to be detectable.   

Analytical Limitations

Interpretation of the test results is limited by the information that is currently available.  Better interpretation should be possible in the future as more data and knowledge about human genetics and this specific disorder are accumulated.

When Sanger sequencing does not reveal any difference from the reference sequence, or when a sequence variant is homozygous, we cannot be certain that we were able to detect both patient alleles.  Occasionally, a patient may carry an allele which does not amplify, due to a large deletion or insertion.   In these cases, the report will contain no information about the second allele.  Our Sanger and NGS Sequencing tests are generally not capable of detecting Copy Number Variants (CNVs).

We sequence all coding exons for each given transcript, plus ~10 bp of flanking non-coding DNA for each exon.  Test reports contain no information about other portions of the gene, such as regulatory domains, deep intronic regions or any currently uncharacterized alternative exons.

In most cases, we are unable to determine the phase of sequence variants.  In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants due to somatic mosaicism is limited.  Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR.

Unless otherwise indicated, DNA sequence data is obtained from a specific cell-type (usually leukocytes from whole blood).   Test reports contain no information about the DNA sequence in other cell-types.

We cannot be certain that the reference sequences are correct.

Rare, low probability interpretations of sequencing results, such as for example the occurrence of de novo mutations in recessive disorders, are generally not included in the reports.

We have confidence in our ability to track a specimen once it has been received by PreventionGenetics.  However, we take no responsibility for any specimen labeling errors that occur before the sample arrives at PreventionGenetics.

Deletion/Duplication Testing via Array Comparative Genomic Hybridization

Test Procedure

Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are analyzed.

Analytical Validity

PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene.

Analytical Limitations

Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.

This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.

aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.

In the case of duplications, aCGH will not determine the chromosomal location of the duplicated DNA. Most duplications will be tandem, but in some cases the duplicated DNA will be inserted at a different locus. This method will also not determine the orientation of the duplicated segment (direct or inverted).

Breakpoints, if occurring outside the targeted gene, may be hard to define.

The sensitivity of this assay is dependent upon the quality of the input DNA. In particular, highly degraded DNA will yield poor results.

Order Kits

Ordering Options

myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.


(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.


(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.


(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×

Copy Text to Clipboard